1-9 of 9
Antonio Rueda
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Martin Hutchings, Anna Sureda Balari, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan P Skarbnik, Raul Cordoba, Judit Mészáros Joergensen, Pier Luigi Zinzani, Ronit Gurion, Neta Goldschmidt, Wilfred Leung, Donghang Li, James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2024) 144 (Supplement 1): 988.
https://doi.org/10.1182/blood-2024-194328
Published: 2024
Journal Articles

Golcadomide (GOLCA; CC-99282), a Novel CELMoD Agent, Plus R-CHOP in Patients (pts) with Previously Untreated Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy Results from Phase 1b Dose Expansion

Marc S. Hoffmann, Javier L. Munoz, Jason Westin, Theodoros Vassilakopoulos, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Wojciech Jurczak, Su-Peng Yeh, Maria Bouzani, Argyrios Gkasiamis, Mark Kaplan, Arpankumar Patel, Floriane Boucaud, Ju Li, Grzegorz S. Nowakowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4459.
https://doi.org/10.1182/blood-2023-174242
Published: 2023
Journal Articles

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study

Martin Hutchings, Abraham Avigdor, Anna Maria Sureda Balari, Maria José Terol, Francesc Bosch, Paolo Corradini, Thomas S. Larsen, Antonio Rueda Dominguez, Alan Skarbnik, Judit Mészáros Joergensen, David Lavie, Ronit Gurion, Pier Luigi Zinzani, Antonio Pinto, Raul Cordoba, Alessia Bottos, Donghang Li, James Relf, Audrey Filézac De L'Étang, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2023) 142 (Supplement 1): 4460.
https://doi.org/10.1182/blood-2023-174213
Published: 2023
Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2021) 138 (Supplement 1): 525.
https://doi.org/10.1182/blood-2021-148359
Published: 2021
Journal Articles

Diffuse Large B Cell Lymphoma Genetic Classification By Targeted Sequencing and Associations with Immunochemotherapy-Treated Patients' Clinical Outcome

Lucia Pedrosa Perez, Ismael Fernández-Miranda, David Perez Callejo, Cristina Quero, Marta Rodriguez, Paloma Martin-Acosta, Sagrario Gomez, Julia González-Rincón, Adrian Santos, Carlos Tarin, Juan F. Garcia, Francisco R García-Arroyo, Antonio Rueda, Francisca I Camacho, Monica Garcia-Cosio, MD, Ana Heredero, Marta Llanos, Manuela Mollejo, Miguel Piris-Villaespesa, José Gómez Codina, MD, Natalia Yanguas-Casás, Antonio Sánchez, Miguel A. Piris, Mariano Provencio, Margarita Sanchez-Beato
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-141193
Published: 2020
Journal Articles

Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study

Radhakrishnan Ramchandren, MD, Michelle A. Fanale, MD, Antonio Rueda, Philippe Armand, MD PhD, Marek Trněný, MD PhD, Tatyana A Feldman, MD, Stephen M Ansell, MD PhD, Mariano Provencio, MD, Ulrich Jaeger, MD, Jonathon B Cohen, MDMS, Kerry J Savage, BSc, MD MSc, Wolfgang Willenbacher, Mariana Sacchi, Anne Sumbul, Eva Domingo Domenech, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 651.
https://doi.org/10.1182/blood.V130.Suppl_1.651.651
Published: 2017
Journal Articles

Post Relapse Survival Rates in Diffuse Large B-Cell Lymphoma

Andrew McMillan, PhD, Alejandro Martín, MD PhD, Corinne Haioun, MD PhD, Annalisa Chiappella, Alice Di Rocco, MD PhD, Antonio Rueda, Christina Palaska, Andrew J Davies, FRCP PhD
Journal: Blood
Blood (2016) 128 (22): 4204.
https://doi.org/10.1182/blood.V128.22.4204.4204
Published: 2016
Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Santiago Montes-Moreno, Ana Batlle, MD, Sonia Gonzalez de Villambrosia, MD, Beatriz Sanchez-Espiridión, PhD, Laura Cereceda, Eva González-Barca, Purroy Noelia, MD, Emilia Pardal, Elena Sebastian, Alejandro Martin, Carlos Grande, Francisco Mazorra, MD, Andrés Insunza, Antonio Rueda, MD, Marta Llanos, MD, Jose Gomez Codina, MD, Francisco Ramon Garcia Arroyo, MD, Dolores Caballero, MD, Eulogio Conde, Andrés Lopez, MD, Mariano Provencio, Miguel Piris, MD
Journal: Blood
Blood (2012) 120 (21): 2672.
https://doi.org/10.1182/blood.V120.21.2672.2672
Published: 2012
Journal Articles

Mabthera (Rituximab) Plus CVP Chemotherapy for First-Line Treatment of Stage III/IV Follicular Non-Hodgkin’s Lymphoma (NHL): Confirmed Efficacy with Longer Follow-Up.

Philippe Solal-Celigny, MD, Kevin Imrie, MD, Andrew Belch, MD, Katherine Sue Robinson, MD, David Cunningham, Antonio Rueda, MD, John Catalano, MD, Fritz Offner, Jan Walewski, MD, João Raposo, MD, Paul Smith, MSc, Robert Marcus, MD
Journal: Blood
Blood (2005) 106 (11): 350.
https://doi.org/10.1182/blood.V106.11.350.350
Published: 2005